2024 Guideline for the Management of Hypertrophic Cardiomyopathy

Writing Committee Chair Steve R. Ommen, MD, FACC, FAHA and Vice Chair Carolyn Ho, MD, FAHA discuss the 2024 updates to the Hypertrophic Cardiomyopathy (HCM) Guidelines. Following U.S. Food and Drug Administration approval of the first cardiac myosin inhibitor mavacamten for symptomatic obstructive HCM, the guideline now includes it as an option before more invasive therapies when first-line treatments like beta blockers or calcium channel blockers are not effective. Additionally, changes in recommendations regarding exercise and activity levels are discussed, emphasizing a more inclusive approach towards physical activity for patients with HCM.

View supporting materials:

[PokemonVibez]

Thank you for this informative video, as someone with noHCM, I appreciate learning something new every day!

[melissasanchez]

Wow!! Thank you both so much for sharing this information! As someone who recently got diagnosed with this genetic disorder I am deeply grateful for alll your hard work and research into this!! ❤️

[franiricci]

Thank you for this update. Can you or anyone else address the cost of this medication. I understand that are some programs to help pay the high cost of this medication based on income if you are at the poverty level or up to 500% above this level. So far I have been denied this level due to my income. How can any average person afford the huge retail cost of this and other medications.

[bhatnagarmb]

Hi. I am writing from India . My son is diagnosed with Non Obstructive LVH . Can you inform if these guidelines apply to him . Since you are talking about Obstructive.

[isabellevince]

Nothing about nutrition, obesity and weight loss.